Abstract
Introduction: Panitumumab is one of the standard targeted agents for metastatic colorectal cancer. The result of previous phase I trial suggest short infusion of panitumumab is tolerable without compromising activity, and a few studies demonstrate its efficacy and safety in combination with irinotecan as a third-line chemotherapy. This phase II study evaluated the efficacy and safety of short infusion of panitumumab with irinotecan in patients with chemotherapy-refractory metastatic colorectal cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
